List of Steglujan drug patents

Steglujan is owned by Merck Sharp Dohme.

Steglujan contains Ertugliflozin; Sitagliptin Phosphate.

Steglujan has a total of 7 drug patents out of which 2 drug patents have expired.

Expired drug patents of Steglujan are:

  • US6699871*PED
  • US6699871

Steglujan was authorised for market use on 19 December, 2017.

Steglujan is available in tablet;oral dosage forms.

Steglujan can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Drug patent challenges can be filed against Steglujan from December, 2021.

The generics of Steglujan are possible to be released after 21 October, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(6 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a day ago)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US9439901 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in